[Federal Register Volume 83, Number 28 (Friday, February 9, 2018)]
[Notices]
[Page 5810]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2018-02646]


-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

[Docket No. DEA-392]


Importer of Controlled Substances Application: Noramco, Inc.

ACTION: Notice of application.

-----------------------------------------------------------------------

DATES: Registered bulk manufacturer of the affected basic classes and 
applicants therefore, may file written comments on or objections to the 
issuance of the proposed registration on or before March 12, 2018. Such 
persons may also file a written request for a hearing on the 
application on or before March 12, 2018.

ADDRESSES: Written comments should be sent to: Drug Enforcement 
Administration, Attention: DEA Federal Register Representative/DRW, 
8701 Morrissette Drive, Springfield, Virginia 22152. All requests for 
hearing must be sent to: Drug Enforcement Administration, Attn: 
Administrator, 8701 Morrissette Drive, Springfield, Virginia 22152. All 
requests for hearing should also be sent to: (1) Drug Enforcement 
Administration, Attn: Hearing Clerk/LJ, 8701 Morrissette Drive, 
Springfield, Virginia 22152; and (2) Drug Enforcement Administration, 
Attn: DEA Federal Register Representative/DRW, 8701 Morrissette Drive, 
Springfield, Virginia 22152. Comments and requests for hearings on 
applications to import narcotic raw material are not appropriate. 72 FR 
3417 (January 25, 2007).

SUPPLEMENTARY INFORMATION: The Attorney General has delegated his 
authority under the Controlled Substances Act to the Administrator of 
the Drug Enforcement Administration (DEA), 28 CFR 0.100(b). Authority 
to exercise all necessary functions with respect to the promulgation 
and implementation of 21 CFR part 1301, incident to the registration of 
manufacturers, distributors, dispensers, importers, and exporters of 
controlled substances (other than final orders in connection with 
suspension, denial, or revocation of registration) has been redelegated 
to the Assistant Administrator of the DEA Diversion Control Division 
(``Assistant Administrator'') pursuant to section 7 of 28 CFR part 0, 
appendix to subpart R.
    In accordance with 21 CFR 1301.34(a), this is notice that on July 
6, 2017, Noramco, Inc., 1550 Olympic Drive, Athens, Georgia 30601 
applied to be registered as an importer of the following basic 
controlled substances:

------------------------------------------------------------------------
                                           Drug
          Controlled substance             code          Schedule
------------------------------------------------------------------------
Marihuana Extract......................     7350  I
Marihuana..............................     7360  I
Tetrahydrocannabinols..................     7370  I
Nabilone...............................     7379  II
Phenylacetone..........................     8501  II
Thebaine...............................     9333  II
Opium, raw.............................     9600  II
Poppy Straw Concentrate................     9670  II
Tapentadol.............................     9780  II
------------------------------------------------------------------------

    The company plans to import phenylacetone (8501), opium, raw 
(9600), and poppy straw concentrate (9670) to bulk manufacture other 
controlled substances for distribution to its customers. The company 
plans to import an intermediate form of tapentadol (9780) to bulk 
manufacture tapentadol (9780) for distribution to its customers. 
Placement of these drug codes onto the company's registration does not 
translate into automatic approval of subsequent permit applications to 
import controlled substances. Approval of permit applications will 
occur only when the registrant's business activity is consistent with 
what is authorized under 21 U.S.C. 952(a)(2). Authorization will not 
extend to the import of FDA approved or non-approved finished dosage 
forms for commercial sale.

    Dated: January 31, 2018.
Susan A. Gibson,
Deputy Assistant Administrator.
[FR Doc. 2018-02646 Filed 2-8-18; 8:45 am]
 BILLING CODE 4410-09-P